OSHQOZON SARATONI ETIOLOGIYASI VA PATOGENEZINING MOLEKULYAR-GENETIK ASOSLARI
Keywords:
oshqozon saratoni, etiologiya, patogenez, molekulyar genetika, kanserogenez, Helicobacter pylori, biomarkerlar, erta tashxis, nishonli (target) terapiya, shaxsiylashtirilgan tibbiyotAbstract
Oshqozon saratoni zamonaviy klinik onkologiyaning eng dolzarb muammolaridan biri bo‘lib, dunyo miqyosida onkologik kasallanish va o‘lim ko‘rsatkichlari bo‘yicha yetakchi o‘rinlardan birini egallaydi. Kasallikdan o‘lim ko‘rsatkichlarining yuqoriligi, asosan, uning kech bosqichlarda aniqlanishi, o‘smaning yuqori biologik agressivligi hamda kanserogenez mexanizmlarining murakkabligi bilan bog‘liq. Hozirgi kunda oshqozon saratoni rivojlanishi tashqi muhit omillari, irsiy moyillik va molekulyar-biologik o‘zgarishlarning o‘zaro ta’siri natijasida yuzaga keladigan ko‘p omilli jarayon ekanligi ilmiy jihatdan isbotlangan. Kasallikning asosiy etiologik omillariga Helicobacter pylori infeksiyasi, Epstein–Barr virusi, surunkali atrofik gastrit, ichak metaplaziyasi, irsiy sindromlar, noto‘g‘ri ovqatlanish, chekish, spirtli ichimliklarni suiiste’mol qilish hamda atrof-muhitning zararli omillari kiradi. Zamonaviy onkologiyada oshqozon saratoni kanserogenezining molekulyar-genetik mexanizmlarini o‘rganishga alohida e’tibor qaratilmoqda. Jumladan, TP53, CDH1, HER2, KRAS va PIK3CA genlaridagi mutatsiyalar, DNK reparatsiyasi jarayonlarining buzilishi, epigenetik o‘zgarishlar hamda hujayra ichidagi signal uzatish yo‘llarining disfunksiyasi o‘smaning rivojlanishi, invaziyasi va metastazlanishida muhim ahamiyatga ega ekanligi aniqlangan.
References
Bray F., Laversanne M., Sung H., et al. Global Cancer Statistics 2024. CA: A Cancer Journal for Clinicians. 2024.
Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide. CA: A Cancer Journal for Clinicians. 2024.
WHO. Classification of Tumours Editorial Board. Digestive System Tumours. 5th ed. Lyon: IARC Press; 2022.
IARC. World Cancer Report 2024. Lyon: International Agency for Research on Cancer; 2024.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2025.
European Society for Medical Oncology. Gastric Cancer: ESMO Clinical Practice Guideline. 2024.
American Society of Clinical Oncology. Management of Gastric Cancer. 2024.
Correa P. Human Gastric Carcinogenesis: A Multistep and Multifactorial Process. Cancer Research. 1992.
Correa P., Piazuelo M.B. The Gastric Precancerous Cascade. Journal of Digestive Diseases. 2012.
Polk D.B., Peek R.M. Helicobacter pylori: Gastric Cancer and Beyond. Nature Reviews Cancer. 2010.
Smyth E.C., Nilsson M., Grabsch H.I., et al. Gastric Cancer. The Lancet. 2020.
Ajani J.A., D'Amico T.A., Bentrem D.J., et al. Gastric Cancer, Version 2. Journal of the National Comprehensive Cancer Network.
Van Cutsem E., Sagaert X., Topal B., et al. Gastric Cancer. The Lancet. 2016.
Lordick F., Carneiro F., Cascinu S., et al. Gastric Cancer: ESMO Clinical Practice Guidelines. Annals of Oncology.
Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature. 2014.
Cristescu R., Lee J., Nebozhyn M., et al. Molecular Analysis of Gastric Cancer. Nature Medicine. 2015.
Lauren P. The Two Histological Main Types of Gastric Carcinoma. Acta Pathologica. 1965.
Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in HER2-positive Gastric Cancer. The Lancet. 2010.
Shah M.A., Ajani J.A. Gastric Cancer — An Update. Current Oncology Reports.
Rugge M., Genta R.M. Staging and Grading of Chronic Gastritis. Human Pathology.





